Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Diabetes

  Free Subscription


Articles published in J Hypertens

Retrieve available abstracts of 119 articles:
HTML format



Single Articles


    February 2025
  1. WONG HJ, Toh KZX, Teo YH, Teo YN, et al
    Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.
    J Hypertens. 2025;43:290-300.
    PubMed     Abstract available


    December 2024
  2. KIM JH, Oh S, Hong SJ, Yu CW, et al
    Minimum number of readings necessary for determining long-term visit-to-visit blood pressure variability to predict cardiovascular outcomes in people with diabetes.
    J Hypertens. 2024 Dec 18. doi: 10.1097/HJH.0000000000003954.
    PubMed     Abstract available


  3. TU Q, Hyun K, Lin S, Hafiz N, et al
    Impacts of hypertension and diabetes on the incidence of cardiovascular diseases and all-cause mortality: findings from the China Health and Retirement Longitudinal Study cohort.
    J Hypertens. 2024 Dec 12. doi: 10.1097/HJH.0000000000003946.
    PubMed     Abstract available


    September 2024
  4. COTTRELL EC
    Commentary on: 'Finger pulse plethysmography predicts gestational hypertension, preeclampsia and gestational diabetes'.
    J Hypertens. 2024;42:1523-1524.
    PubMed    


  5. SHU TT, Gao ZX, Mao ZH, Yang YY, et al
    Defective natriuresis contributes to hyperkalemia in db/db mice during potassium supplementation.
    J Hypertens. 2024;42:1632-1640.
    PubMed     Abstract available


    August 2024
  6. WANG N, Chalmers J, Harris K, Poulter N, et al
    Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial.
    J Hypertens. 2024 Aug 27. doi: 10.1097/HJH.0000000000003855.
    PubMed     Abstract available


  7. COTE N, Fortier C, Jafari K, Pare M, et al
    Estimated versus measured aortic stiffness: implications of diabetes, chronic kidney disease, sex and height.
    J Hypertens. 2024 Aug 26. doi: 10.1097/HJH.0000000000003845.
    PubMed     Abstract available


    May 2024
  8. SHAHRBABAKI SS, Liu X, Baumert M
    Finger pulse plethysmography predicts gestational hypertension, preeclampsia and gestational diabetes.
    J Hypertens. 2024 May 15. doi: 10.1097/HJH.0000000000003775.
    PubMed     Abstract available


    April 2024
  9. SASAKI N, Maeda R, Ozono R, Yoshimura K, et al
    Differences in the impact of newly diagnosed type 2 diabetes on cardiovascular mortality between normotensive and hypertensive individuals.
    J Hypertens. 2024;42:610-619.
    PubMed     Abstract available


  10. BARCELLOS PAM, Dall'Agnol A, Sandi GM, Remonti LR, et al
    Dietary approach for the treatment of arterial hypertension in patients with diabetes mellitus.
    J Hypertens. 2024;42:583-593.
    PubMed     Abstract available


  11. WANG R, Zhao J, Li L, Huo Y, et al
    Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
    J Hypertens. 2024;42:727-734.
    PubMed     Abstract available


    March 2024
  12. MAVROGEORGIS E, Kondyli M, Mischak H, Vlahou A, et al
    Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology.
    J Hypertens. 2024 Mar 29. doi: 10.1097/HJH.0000000000003726.
    PubMed     Abstract available


  13. KOLLIAS A, Kyriakoulis KG, Komnianou A, Stathopoulou P, et al
    Prognostic value of home versus ambulatory blood pressure monitoring: a systematic review and meta-analysis of outcome studies.
    J Hypertens. 2024;42:385-392.
    PubMed     Abstract available


    February 2024
  14. TARKKONEN A, Fickweiler W, Eriksson M, Sun JK, et al
    Retinal artery to vein ratio is associated with cerebral microbleeds in individuals with type 1 diabetes.
    J Hypertens. 2024 Feb 28. doi: 10.1097/HJH.0000000000003690.
    PubMed     Abstract available


  15. ZHANG L, Wang W, Gong J, Wang X, et al
    Development, validation, and clinical utility of a risk prediction model for recurrent preeclampsia.
    J Hypertens. 2024;42:236-243.
    PubMed     Abstract available


    January 2024

  16. Reply to 'Diabetes and orthostatic hypotension: are all patients treated equal?': Erratum.
    J Hypertens. 2024;42:195.
    PubMed    


    December 2023
  17. SASAGAWA Y, Inoue Y, Futagami K, Nakamura T, et al
    Application of deep neural survival networks to the development of risk prediction models for diabetes mellitus, hypertension, and dyslipidemia.
    J Hypertens. 2023 Dec 14. doi: 10.1097/HJH.0000000000003626.
    PubMed     Abstract available


  18. CRUZ-LOPEZ EO, Ye D, Stolk DG, Clahsen-van Groningen MC, et al
    Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.
    J Hypertens. 2023 Dec 11. doi: 10.1097/HJH.0000000000003633.
    PubMed     Abstract available


    October 2023
  19. RIJAL A, Adhikari TB, Dhakal S, Maagaard M, et al
    Effects of adding exercise to usual care on blood pressure in patients with hypertension, type 2 diabetes, or cardiovascular disease: a systematic review with meta-analysis and trial sequential analysis.
    J Hypertens. 2023 Oct 6. doi: 10.1097/HJH.0000000000003589.
    PubMed     Abstract available


    August 2023
  20. ABUSHAMAT LA, Enge D, Fujiwara T, Schafer M, et al
    Obesity dominates early effects on cardiac structure and arterial stiffness in people with type 2 diabetes.
    J Hypertens. 2023 Aug 18. doi: 10.1097/HJH.0000000000003534.
    PubMed     Abstract available


    July 2023
  21. BERETTA MV, Hoffmeinster M, da Costa Rodrigues T
    Reply to 'Diabetes and orthostatic hypotension: are all patients treated equal?'.
    J Hypertens. 2023;41:1219-1220.
    PubMed    


  22. CUSPIDI C, Gherbesi E, Tadic M
    Diabetes and orthostatic hypotension: are all patients created equal?
    J Hypertens. 2023;41:1217-1218.
    PubMed    


    April 2023
  23. GAO ZX, Wei QC, Shu TT, Li ST, et al
    Kir4.1 deletion prevents salt-sensitive hypertension in early streptozotocin-induced diabetic mice via Na+-Cl- cotransporter in the distal convoluted tubule.
    J Hypertens. 2023 Apr 5. doi: 10.1097/HJH.0000000000003419.
    PubMed     Abstract available


    March 2023
  24. XIONG S, Yin S, Deng W, Zhao Y, et al
    Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population.
    J Hypertens. 2023 Mar 2. doi: 10.1097/HJH.0000000000003394.
    PubMed     Abstract available


  25. KOBAYASHI A, Fujihara K, Yamada MH, Sato T, et al
    Combined effects of blood pressure and glycemic status on risk of heart failure: a population-based study.
    J Hypertens. 2023;41:470-475.
    PubMed     Abstract available


    February 2023
  26. CARDOSO CRL, Leite NC, Salles GF
    Relative prognostic importance of aortic and brachial blood pressures for cardiovascular and mortality outcomes in patients with resistant hypertension and diabetes: a two cohorts prospective study.
    J Hypertens. 2023 Feb 2. doi: 10.1097/HJH.0000000000003387.
    PubMed     Abstract available


  27. KAWADA T
    Cardiovascular disease risk in patients with type 2 diabetes and hypertension.
    J Hypertens. 2023;41:365.
    PubMed    


  28. AGARWAL R, Ruilope LM, Ruiz-Hurtado G, Haller H, et al
    Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
    J Hypertens. 2023;41:295-302.
    PubMed     Abstract available


  29. ISAKSSON GL, Nielsen LH, Palarasah Y, Jensen DM, et al
    Urine excretion of C3dg and sC5b-9 coincide with proteinuria and development of preeclampsia in pregnant women with type-1 diabetes.
    J Hypertens. 2023;41:223-232.
    PubMed     Abstract available


  30. ZHOU TL, Reulen JPH, Van Der Staaij H, Stehouwer CDA, et al
    Cardiovagal baroreflex sensitivity, blood pressure and blood pressure variability - the Maastricht study.
    J Hypertens. 2023;41:254-261.
    PubMed     Abstract available


    December 2022
  31. BERETTA MV, Milan VB, Hoffmeister MC, Rodrigues TC, et al
    Orthostatic hypotension, falls and in-hospital mortality among elderly patients with and without type 2 diabetes.
    J Hypertens. 2022 Dec 23. doi: 10.1097/HJH.0000000000003338.
    PubMed     Abstract available


  32. TEO YH, Chia AZQ, Teo YN, Chong EY, et al
    The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
    J Hypertens. 2022;40:2353-2372.
    PubMed     Abstract available


    November 2022
  33. JIN S, Reesink KD, Kroon AA, de Galan B, et al
    Complement factors D and C3 cross-sectionally associate with arterial stiffness, but not independently of metabolic risk factors: The Maastricht Study.
    J Hypertens. 2022;40:2161-2170.
    PubMed     Abstract available


    October 2022
  34. HELLEPUTTE S, Spronck B, Sharman JE, Van Bortel L, et al
    Central blood pressure estimation in type 1 diabetes: impact and implications of peripheral calibration method.
    J Hypertens. 2022 Oct 10. pii: 00004872-990000000-00126.
    PubMed     Abstract available


    August 2022
  35. ARAUJO-CASTRO M, Paja Fano M, Gonzalez Boillos M, Pla Peris B, et al
    Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score.
    J Hypertens. 2022 Aug 24. pii: 00004872-990000000-00101.
    PubMed     Abstract available


  36. MARCON D, Tagetti A, Piona C, Giontella A, et al
    Markers of subclinical vascular damage in young adults with type 1 diabetes mellitus: the role of central blood pressure.
    J Hypertens. 2022 Aug 23. pii: 00004872-990000000-00096.
    PubMed     Abstract available


  37. HATA S, Ushigome E, Yoshimura T, Takegami M, et al
    Maximum home blood pressure and cardiovascular outcomes in patients with type 2 diabetes: KAMOGAWA-HBP study.
    J Hypertens. 2022 Aug 19. pii: 00004872-990000000-00088.
    PubMed     Abstract available


  38. BARDEN AE, Shinde S, Phillips M, Beilin LJ, et al
    Mediators of inflammation resolution and vasoactive eicosanoids in gestational diabetes and preeclampsia.
    J Hypertens. 2022 Aug 9. pii: 00004872-990000000-00076.
    PubMed     Abstract available


    July 2022
  39. BIRUKOV A, Glintborg D, Schulze MB, Jensen TK, et al
    Elevated blood pressure in pregnant women with gestational diabetes according to the WHO criteria: importance of overweight.
    J Hypertens. 2022 Jul 6. pii: 00004872-990000000-00028.
    PubMed     Abstract available


    June 2022
  40. UAGBOE AA, Ogboye A, Munee MM, Rahman KJ, et al
    LEVERAGING TECHNOLOGY TO SUPPORT PEOPLE LIVING WITH HYPERTENSION AND DIABETES DURING THE COVID-19 PANDEMIC.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  41. TARKKONEN A, Fickweiler W, Sun J, Thorn L, et al
    CHANGES IN RETINAL VESSEL DIAMETER ARE ASSOCIATED WITH CEREBRAL MICROBLEEDS IN NEUROLOGICALLY ASYMPTOMATIC INDIVIDUALS WITH TYPE 1 DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  42. BARRAGAN ACP, Leiva VG, Espejel LD
    REACHING OF THERAPEUTICS GOALS IN PATIENTS WITH HYPERTENSION AND DIABETES MELLITUS. DO MULTIPLE THERAPY WORKS?
    J Hypertens. 2022;40.
    PubMed     Abstract available


  43. DOAN L
    EFFICACY OF SGLT2I IN ACUTE DECOMPENSATED HEART FAILURE WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  44. PATOULIAS D, Katsimardou A, Boulmpou A, Imprialos K, et al
    META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  45. PAFFER MT, Paffer PT, Paffer T, Castro C, et al
    ARTERIAL STIFFNESS ASSESSMENT IN DIABETIC PATIENTS IN A CARDIOLOGY CLINIC.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  46. MANUKYAN M, Falkovskaya A, Mordovin V, Zyubanova I, et al
    SYSTEMIC VASCULAR RESISTANCE AS A PREDICTOR OF ANTIHYPERTENSIVE EFFICIENCY OF RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  47. BOSCH A, Poglitsch M, Kannenkeril D, Ott C, et al
    ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  48. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    FEATURES OF CHANGES IN THE LEVELS OF MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN DIABETIC PATIENTS WITH RESISTANT HYPERTENSION AFTER RENAL DENERVATION.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  49. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    THE EFFECT OF RENAL DENERVATION ON CEREBRAL BLOOD FLOW IN DIABETIC PATIENTS WITH RESISTANT HYPERTENSION.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  50. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    THE EFFECT OF RENAL DENERVATION ON PERIPHERAL AND CEREBRAL VASOREACTIVITY IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  51. MANUKYAN M, Falkovskaya A, Mordovin V, Zyubanova I, et al
    LEPTIN AS A PREDICTOR OF CARDIOPROTECTIVE EFFICIENCY OF RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  52. ANYFANTI P, Nikolaidou B, Gavriilaki E, Triantafyllou A, et al
    MICRO- AND MACROVASCULAR ALTERATIONS IN RHEUMATOID ARTHRITIS COMPARED TO TYPE 2 DIABETES MELLITUS: EVIDENCE OF SIMILAR DEGREE OF ORGAN DAMAGE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  53. SHORIKOVA D, Shorikov E, Shorikov P, Ismael O, et al
    POLYMORPHISMS NOS3-T-786C IN MACROANGIOPATHIES IN PATIENTS WITH COMBINED HYPERTENSION AND TYPE DIABETES MELLITUS 2.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  54. ZERVAKIS S, Marketou M, Plevritaki A, Kontaraki J, et al
    MICRORNA PROFILE ANALYSIS IN PERICORONARY ADIPOSE TISSUE OF DIABETIC PATIENTS WITH SIGNIFICANT CORONARY ARTERY DISEASE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  55. GEORGIANOU E, Markakis K, Georgianos P, Zografou I, et al
    PREVALENCE AND CONTROL OF HYPERTENSION IN DIABETIC PATIENTS WITH VERSUS WITHOUT CHRONIC KIDNEY DISEASE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  56. MIRADA M, Pessana F, Acuna MIR, Ramirez A, et al
    ARTERIAL HYPERTENSION (HT) IS ONE OF THE MOST PREDICTIVE RISK FACTORS FOR TYPE 2 DIABETES (DM2). THE FINDRISC IS VALIDATED FOR THE EARLY DETECTION OF SUFFERING FROM DM2.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  57. RODERO EMA, Esmeral LPM, Mogollon LGR, Charris MA, et al
    ASSOCIATION BETWEEN THE TIME OF EVOLUTION AND LIFESTYLES WITH ADHERENCE TO TREATMENT FOR DIABETES MELLITUS. BARRANQUILLA COLOMBIA.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  58. RODERO EMA, Esmeral LPM, Contrera ME, Charris MA, et al
    LEVEL OF ADHERENCE TO THE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT OF PATIENTS WITH DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  59. PAPAVASILEIOU M, Aravantinos D, Karamanou A, Moustakas G, et al
    PROGNOSTIC VALUE OF THE GLYCOSYLATED HEMOGLOBIN TO THE MACE IN HYPERTENSIVE NON DIABETIC PATIENTS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  60. LOPEZ EOC, Ren L, Uijl E, Clahsen-Van Groningen MC, et al
    BLOOD PRESSURE-INDEPENDENT RENOPROTECTION IN DIABETIC RATS TREATED WITH SMALL INTERFERING RNA TARGETING LIVER ANGIOTENSINOGEN.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  61. DOAN L
    SGLT2I - A POTENTIAL ANTIHYPERTENSIVE AGENT IN HYPERTENSION PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  62. GEORGIANOU E, Markakis K, Georgianos P, Zografou I, et al
    THE ASSOCIATION OF EGFR AND ALBUMINURIA WITH SYSTOLIC HYPERTENSION IN PATIENTS WITH DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  63. HELLEPUTTE S, Spronck B, Sharman J, Bortel LV, et al
    CENTRAL BLOOD PRESSURE ESTIMATION IN TYPE 1 DIABETES: IMPACT OF PERIPHERAL BLOOD PRESSURE CALIBRATION APPROACH.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  64. HILL J, Faber M, De Villiers A, Mulabisano T, et al
    DEVELOPMENT OF TEXT-MESSAGING TO SUPPORT THE SOUTH AFRICAN DIABETES PREVENTION PROGRAM.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  65. HILL J, Yako Y, Rusike C, Toni S, et al
    APPLICABILITY OF THE SOUTH AFRICAN DIABETES PREVENTION PROGRAMME IN THE EASTERN CAPE PROVINCE OF SOUTH AFRICA: A STUDY PROTOCOL.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  66. LEBEDEV D, Lyasnikova E, Vasilyeva E, Sitnikova M, et al
    PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  67. MARCON D, Tagetti A, Giontella A, Bortolotti S, et al
    SUBCLINICAL VASCULAR DAMAGE IN YOUNG ADULTS WITH TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  68. NELAJ E, Kecaj I, Gjata M, Tase M, et al
    ATHEROSCLEROSIS AND INCIPIENT NEPHROPATHY IN DIABETIC PATIENTS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  69. NIKOLAIDOU B, Triantafyllou A, Anyfanti P, Gavriilaki E, et al
    STUDY OF EARLY RETINAL CHANGES IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  70. PATOULIAS D, Katsimardou A, Stavropoulos K, Imprialos K, et al
    CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETICS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  71. PATOULIAS D, Toumpourleka M, Katsimardou A, Zografou I, et al
    BENEFICIAL EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON RIGHT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PILOT, OBSERVATIONAL STUDY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  72. PATOULIAS D, Siskos F, Katsimardou A, Imprialos K, et al
    META-ANALYSIS ADDRESSING THE EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON FLOW-MEDIATED DILATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  73. PEER N, Nguyen K, Hill J, Kengne AP, et al
    PREVALENCE OF DIABETES AND PREDIABETES AMONG ADULTS WITH HIV IN AFRICA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  74. RAMIREZ AJ, Pessana F, Sanchez MJ, Sanchez RA, et al
    CANAGLIFLOZIN IS MORE EFFECTIVE THAN PERINDOPRIL TO IMPROVE RENAL HYPERFILTRATION AND URINARY ALBUMIN EXCRETION IN TYPE 2 DIABETES PATIENTS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  75. MARTINEZ F, Calderon JM, Sauri I, Fernandez A, et al
    REAL WORLD IMPACT OF BLOOD PRESSURE CHANGES ON MORBIDITY AND MORTALITY IN TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  76. RUS H, Poinareanu I, Bobescu E
    EFFECT OF EMPAGLIFOZIN ON 24-HOUR BLOOD PRESSURE, BRACHYAL ENDOTHELIAL DYSFUNCTON, AND LEFT VENTRICULAR DIASTOLIC FUNCTION, IN PATIENTS WITH TYPE-2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  77. SEMIANIV M, Semianiv I
    THE RISK OF COMBINED PATHOLOGY OF DIABETES MELLITUS AND TUBERCULOSIS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  78. BOUNTZONA I, Kollias A, Kyriakoulis K, Destounis A, et al
    NIGHT-TIME BLOOD PRESSURE ASSESSED BY HOME VS. AMBULATORY MONITORING IN ADULTS WITH TYPE 2 DIABETES: ASSOCIATION WITH PRECLINICAL TARGET ORGAN DAMAGE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  79. MENTI A, Kollias A, Bountzona I, Konstantakopoulos S, et al
    NIGHT-TIME BLOOD PRESSURE IN DIABETES TYPE-1 ASSESSED BY HOME VS. AMBULATORY MONITORING: A PILOT STUDY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  80. WANG Q, Tian L, Sun R, Qi M, et al
    EFFECTS OF SGLT-2 INHIBITORS ON 24H AMBULATORY BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC AND HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  81. CHALAKOVA T, Tsochev K, Yotov Y, Bocheva Y, et al
    ARTERIAL HYPERTENSION IN PATIENTS WITH LONG DURATION TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  82. ZEMMOUCHI S
    THE SPECIFICS OF HEMODIALYSIS IN DIABETICS. EASTERN ALGERIAN EXPERIENCE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  83. ZHURAVLYOVA L, Rogachova T, Sokolnikova N, Filonenko M, et al
    THE EFFECT OF DAPAGLIFLOZIN ON THE LEVEL OF SYSTOLIC BLOOD PRESSURE AND GLYCEMIC CONTROL IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  84. MONTEALEGRE L, Amador E, Pulido T, Rebolledo R, et al
    FACTORS THAT INFLUENCE THE SURVIVAL RATE IN PATIENTS WITH COVID-19 WITH A PREVIOUS DIAGNOSIS OF HYPERTENSION AND/OR DIABETES: A SYSTEMATIC REVIEW.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  85. IOANNIDIS A, Pechlevanis A, Fragkiskou A, Asmani F, et al
    SELF-REPORTED CHANGE IN (UN)HEALTHY BEHAVIOURS OF PATIENTS WITH CARDIOVASCULAR DISEASES DURING THE SECOND COVID-19 LOCKDOWN IN NORTHERN GREECE: FOCUS ON DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  86. JAIN R, Hosseini J, Shoghli R
    COVID19 INFECTION IN CORONARY ARTERY DISEASE WITH DIABETES AND HYPERTENSION IN VALVULAR SURGERY PATIENTS IN TERTIARY HEART CENTRE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  87. PATOULIAS D, Katsimardou A, Toumpourleka M, Boulmpou A, et al
    EFFECT OF SGLT-2 INHIBITORS ON THE RISK FOR ANGINA IN PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS: A META-ANALYSIS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  88. PATOULIAS D, Katsimardou A, Imprialos K, Stavropoulos K, et al
    GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT DECREASE THE RISK FOR CORONARY REVASCULARIZATION IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  89. PATOULIAS D, Katsimardou A, Sviggou A, Kordalis V, et al
    MAJOR ADVERSE EVENTS WITH THE USE OF FINERENONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  90. BORTOLOTTI S, Cattazzo F, Tagetti A, Marcon D, et al
    CARDIOVASCULAR RISK FACTORS IN TYPE 1 DIABETES MELLITUS: ANY DIFFERENCE BETWEEN ADOLESCENTS AND YOUNG ADULTS FOR SUBCLINICAL ATHEROSCLEROSIS?
    J Hypertens. 2022;40.
    PubMed     Abstract available


  91. NIELSEN S, Nyvad J, Christensen KL, Poulsen PL, et al
    OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH INCREASED CORONARY CALCIFICATION AND ARTERIAL STIFFNESS IN PATIENTS WTH DIABETIC NEPHROPATHY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  92. SECIN AAR, Moreno FJA, Martinez TR, Rivero JB, et al
    PREVALENCE OF TARGET ORGAN DAMAGE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN IBERICAN STUDY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  93. SILVA AF, Cruz RC, Albuquerque NLS, Silva VM, et al
    METHODS AND NUMBER OF BLOOD PRESSURE ASSESSMENTS USED TO ASSESS BLOOD PRESSURE VARIABILITY IN INDIVIDUALS WITH DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  94. SILVA S, Sousa AC, Sousa AL, Vitorino P, et al
    BEHAVIOR OF PRESSURE VARIABILITY IN PATIENTS WITH ARTERIAL HYPERTENSION AND DIABETES MELLITUS WITH OR WITHOUT INSULIN USE AND THE INFLUENCE OF THE NUTRITIONAL STATE IN BRAZIL.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  95. SOUSA AC, Magalhaes FG, Silva SB, Simeoni AR, et al
    ASSOCIATION OF SHORT-TERM BLOOD PRESSURE VARIABILITY WITH DIABETES IN HYPERTENSIVE INDIVIDUALS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  96. BEREZIN A, Fushtey I, Berezin A
    UTILITY OF IRISIN AND APELIN IN PREDICTION OF HEART FAILURE PHENOTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  97. NIKOLAIDOU B, Anyfanti P, Gavriilaki E, Dolgyras P, et al
    DIABETIC STATUS AND NIGHT-TIME SYSTOLIC BLOOD PRESSURE PREDICT EARLY MYOCARDIAL DAMAGE IN NEWLY DIAGNOSED DIABETES MELLITUS TYPE 2 PATIENTS AS THIS IS DEPICTED BY GALECTIN-3 LEVELS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  98. BENDIAB NT, Bouanane S, Baba Ahmed FZ
    EVALUATION OF PLASMA HOMOCYSTEINE LEVELS AND ERYTHROCYTE ANTIOXIDANT ENZYMATIC ACTIVITIES IN TYPE 2 DIABETICS WITH ARTERIAL HYPERTENSION.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  99. SHAMANNA P, Joshi S, Shah L, Dharmalingam M, et al
    CORRELATION OF DIABETES REMISSION WITH REDUCTIONS IN BLOOD PRESSURE AND CARDIOVASCULAR RISK SCORES: RESULTS OF SIX MONTHS OF RANDOMISED TRIAL WITH DIGITAL TWIN TECHNOLOGY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  100. THANH HN, Trong KHP, Huu AN, Xuan GNT, et al
    PREVALENCE OF HYPERTENSION AND DISTRIBUTION OF BODY MASS INDEX LEVELS AMONG OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS IN VIETNAM: A MULTICENTRE STUDY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  101. KUZIOR A, Hernandez-Lazaro A, De Leon-Durango R, Rios-Gomez C, et al
    INITIATION OF EMPAGLIFLOZIN THERAPY IS ASSOCIATED WITH A CLINICALLY RELEVANT DECREASE IN BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND UNCONTROLLED HYPERTENSION.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  102. ALBA-LINARES JJ, Fernandez-Perez R, Ponce-Zanon F, Garcia-Carbonell N, et al
    MATERNAL OBESITY AND GESTATIONAL DIABETES ARE ASSOCIATED WITH DNA METHYLATION ALTERATIONS IN THE OFFSPRING THROUGHOUT THE FIRST YEAR OF LIFE.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  103. NORDB OP, Landolt L, Eikrem O, Scherer A, et al
    COMPARATIVE TRANSCRIPTOMIC ANALYSIS IDENTIFIES EPITHELIAL-MESENCHYMAL TRANSITION AND INFLAMMATION AS COMMON PATHOGENETIC MECHANISMS IN HYPERTENSIVE AND DIABETIC NEPHROPATHY.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  104. JENKINS S, Gupta P, Khunti K, Cross A, et al
    THE EFFECT OF BIOFEEDBACK ON HYPERTENSION AND DIABETES: PRELIMINARY RESULTS FROM A SYSTEMATIC REVIEW.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  105. TIMASHEVA Y, Balkhiyarova Z, Prokopenko I
    DISENTANGLING THE SHARED HERITABILITY OF THE PREDISPOSITION TO HYPERTENSION AND TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    PubMed     Abstract available


  106. SANZ-GOMEZ M, Vega-Martin E, Gonzalez-Moreno D, Pizzamiglio C, et al
    FINERENONE PREVENTS RENAL AND VASCULAR DAMAGE IN A NOVEL MODEL OF TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    PubMed     Abstract available


    March 2022
  107. KAWADA T
    Comment on 'Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease'.
    J Hypertens. 2022;40:624.
    PubMed    


    February 2022
  108. GENG Q, Hou F, Zhang Y, Wang Z, et al
    Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis.
    J Hypertens. 2022 Feb 25. pii: 00004872-900000000-96482.
    PubMed     Abstract available


  109. VAN DER LINDEN EL, Meeks KAC, Klipstein-Grobusch K, Bahendeka S, et al
    Hypertension determinants among Ghanaians differ according to location of residence: the Research on Obesity and Diabetes among African Migrants study.
    J Hypertens. 2022 Feb 11. pii: 00004872-900000000-96494.
    PubMed     Abstract available


  110. BRADY TM, Horst G, Appel LJ, Khoury PR, et al
    Dietary sodium intake and sodium load is associated with arterial stiffness in children and young adults.
    J Hypertens. 2022;40:292-299.
    PubMed     Abstract available


    January 2022
  111. WANG Y
    Stage 1 hypertension and risk of cardiovascular disease mortality in United States adults with or without diabetes.
    J Hypertens. 2022 Jan 31. pii: 00004872-900000000-96504.
    PubMed     Abstract available


    December 2021
  112. SIAFI E, Andrikou I, Konstantinidis D, Kakouri N, et al
    Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus.
    J Hypertens. 2021;39:2470-2477.
    PubMed     Abstract available


    November 2021
  113. GIUDICI A, Palombo C, Kozakova M, Morizzo C, et al
    Noninvasive carotid pressure-diameter loops to identify viscoelastic properties in ageing, hypertension and type 2 diabetes.
    J Hypertens. 2021;39:2307-2317.
    PubMed     Abstract available


    September 2021
  114. NOLDE JM, Frost S, Kannenkeril D, Lugo-Gavidia LM, et al
    Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure.
    J Hypertens. 2021;39:1826-1834.
    PubMed     Abstract available


    August 2021
  115. THANGARAJ SS, Oxlund CS, Fonseca MPD, Svenningsen P, et al
    The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-[gamma] and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension.
    J Hypertens. 2021 Aug 23. pii: 00004872-900000000-96579.
    PubMed     Abstract available


    July 2021
  116. CARRA MC, Fessi S, Detzen L, Darnaud C, et al
    Self-reported periodontal health and incident hypertension: longitudinal evidence from the NutriNet-Sante e-cohort.
    J Hypertens. 2021 Jul 13. pii: 00004872-900000000-96626.
    PubMed     Abstract available


    November 2020
  117. MURRAY HORWITZ ME, Rodriguez MI, Dissanayake M, Carmichael SL, et al
    Postpartum health risks among women with hypertensive disorders of pregnancy, California 2008-2012.
    J Hypertens. 2020 Nov 18. doi: 10.1097/HJH.0000000000002711.
    PubMed     Abstract available


    August 2020
  118. LIU X, Song Q, Wu S, Zhou W, et al
    Prediabetes and risk for myocardial infarction by hypertension status in a Chinese population: a prospective cohort study.
    J Hypertens. 2020 Aug 29. doi: 10.1097/HJH.0000000000002607.
    PubMed     Abstract available


    July 2020
  119. SAVOIA C, De Ciuceis C, Paini A, Carletti R, et al
    Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.
    J Hypertens. 2020 Jul 27. doi: 10.1097/HJH.0000000000002595.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.